Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | QPCT | Q16769 | 1/20 | 0.49 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.49 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | HMOX1 | P09601 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28857752 | 0.84 | CYP19A1 (0.51) | CYP11B1CYP11B2CYP19A1HMOX1 | |
| SCHEMBL10247576 | 0.81 | TSHR (0.50) | CYP11B1CYP11B2CYP19A1TBXAS1CYP1A2 | |
| SCHEMBL11086199 | 0.80 | CYP11B1 (0.38) | CYP11B1CYP11B2CYP19A1TBXAS1CYP1A2 | |
| Hydrochloric Acid SCHEMBL410844 | 0.80 | TSHR (0.49) | CYP11B1CYP11B2CYP19A1TBXAS1CYP1A2 | |
| SCHEMBL9313112 | 0.75 | CYP11B1 (0.46) | CYP11B1CYP11B2CYP19A1TBXAS1CYP1A2 | |
| SCHEMBL4431612 | 0.75 | HMOX1 (0.40) | CYP11B1CYP11B2CYP19A1TBXAS1CYP1A2 | |
| SCHEMBL10495386 | 0.75 | CYP11B1 (0.40) | CYP11B1CYP11B2CYP19A1TBXAS1CYP1A2 | |
| SCHEMBL10853713 | 0.74 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP17A1HMOX1 | |
| SCHEMBL10850007 | 0.74 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP19A1CYP17A1HMOX1 | |
| SCHEMBL10854958 | 0.73 | CYP11B1 (0.47) | CYP11B1CYP11B2CYP19A1TBXAS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101400656-A | Piperazine derivatives as farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2009-04-01 | — | — | CN | disclosed |
| EP-1973882-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| CN-1326850-C | Tricyclic farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| US-6740661-B2 | TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS | SCHERING CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-6372747-B1 | ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2002-04-16 | — | — | US | disclosed |
| CN-1334811-A | Tricyclic farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2002-02-06 | — | — | CN | disclosed |
| EP-1140902-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037459-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | CYP11B1 1991/4885CYP11B2 2663/4885CYP19A1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.